EXPLORING HIV-1 TAT PENETRABILITY IN TUMOR SPHEROIDS THROUGH CONFOCAL MICROSCOPY: A CELL LINES BASED STUDY

Main Article Content

Aziz Ur Rahman
Abdullah
Muhammad Masoom Akhtar
Sheikh Abdur Rashid
Pervaiz Akhtar Shah
Mobina Manzoor
Jahangir Khan
Saima Mahmood
Rukhsana Ghaffar
Saeed Ahmad
Tariq Javed

Keywords

Peptide drug carrier, Multicellular tumor spheroids, In-vitro tumor model, Quantitive measurement, Confocal microscopy, Trans-activation

Abstract

Deficient vascular supply, intracellular matrix and hypoxia in solid tumor offer  hindrance to penetration of drugs into desired site of action. HIV-1 TAT (Human Immunodiffiency Virus type-1 Transactivation of Transcription) peptide reported to penetrate in all stages of cell cycle, and therefore, could be exploited as potential drug carrier to overcome the penetratibility hindrance into resistant tumor tissues. Multicellular tumor spheroids (MCTS) is an in-vitro tumor model to measure the penetration of TAT to mimic with in-vivo tumors. The current study involves  investigation of the penetration rate, penetration depth, peptide accummulation, and extent of TAT penetration in MCTS at 4°C and 37°C for an incubation time of  1.5 hours. Observations were taken at 10 minutes  interval, from spheroid surface to the deeper layers through 3µm continous laser sectioning. TAT-labelled fluorescence accumulated approximately at the same rate at each observed depth of MCTS. Moreover, higher accummulation in three-day old spheroids was observed, that could be due to loose packed cells, more ratio of extracellular volume, and more number of live proliferating cells as compared to five-day old spheroids. Detection of penetration and fluorescence accummulation decreased as spheroids get older, that dependent on multifunctional characteristic along age/duration of cell culture.

Abstract 43 | pdf Downloads 8

References

1. M. Millard, I. Yakavets, V. Zorin, A. Kulmukhamedova, S. Marchal, L. Bezdetnaya, Drug delivery to solid tumors: The predictive value of the multicellular tumor spheroid model for nanomedicine screening, Int J Nanomedicine, 12 (2017) 7993.
2. G. Mehta, A.Y. Hsiao, M. Ingram, G.D. Luker, S. Takayama, Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy, Journal of controlled release : official journal of the Controlled Release Society, 164 (2012) 192-204.
3. I.M. Kaplan, J.S. Wadia, S.F. Dowdy, Cationic TAT peptide transduction domain enters cells by macropinocytosis, yes, 102 (2005) 247-253.
4. A.I. Minchinton, I.F. Tannock, Drug penetration in solid tumours, Nat Rev Cancer, 6 (2006) 583-592.
5. A. Ur Rahman, S. Khan, M. Khan, Transport of trans-activator of transcription (TAT) peptide in tumour tissue model: evaluation of factors affecting the transport of TAT evidenced by flow cytometry, Journal of Pharmacy and Pharmacology.
6. L. Patel, J. Zaro, W.-C. Shen, Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives, Pharmaceutical Research, 24 (2007) 1977-1992.
7. D. Mann, A. Frankel, Endocytosis and targeting of exogenous HIV-1 TAT protein, The EMBO journal, 10 (1991) 1733-1739.
8. M. Hällbrink, A. Florén, A. Elmquist, M. Pooga, T. Bartfai, Ü. Langel, Cargo delivery kinetics of cell-penetrating peptides, Biochimica et Biophysica Acta (BBA) - Biomembranes, 1515 (2001) 101-109.
9. J.C. Mai, H. Shen, S.C. Watkins, T. Cheng, P.D. Robbins, Efficiency of Protein Transduction Is Cell Type-dependent and Is Enhanced by Dextran Sulfate, J. Biol. Chem., 277 (2002) 30208-30218.
10. G. Tunnemann, R.M. Martin, S. Haupt, C. Patsch, F. Edenhofer, M.C. Cardoso, Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells, FASEB J., 20 (2006) 1775-1784.
11. S.D. Conner, S.L. Schmid, Regulated portals of entry into the cell, Nature, 422 (2003) 37-44.
12. P. Watson, A.T. Jones, D.J. Stephens, Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells, Advanced Drug Delivery Reviews, 57 (2005) 43-61.
13. P. Järver, Ü. Langel, Cell-penetrating peptides--A brief introduction, Biochimica et Biophysica Acta (BBA) - Biomembranes, 1758 (2006) 260-263.
14. A. Chauhan, A. Tikoo, A.K. Kapur, M. Singh, The taming of the cell penetrating domain of the HIV TAT: Myths and realities, yes, 117 (2007) 148-162.
15. J. Liu, F. Yan, H. Chen, W. Wang, W. Liu, K. Hao, G. Wang, F. Zhou, J. Zhang, A novel individual‐cell‐based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin‐related delivery in avascular regions, British journal of pharmacology, 174 (2017) 2862-2879.
16. B. Gupta, T.S. Levchenko, V.P. Torchilin, Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides, Advanced Drug Delivery Reviews, 57 (2005) 637-651.
17. J. Howl, I.D. Nicholl, S. Jones, The many futures for cell-penetrating peptides: how soon is now?, Biochemical Society Transactions, 035 (2007) 767-769.
18. M. Green, P.M. Loewenstein, Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT trans-activator protein, Cell, 55 (1988) 1179-1188.
19. A.D. Frankel, C.O. Pabo, Cellular uptake of the TAT protein from human immunodeficiency virus, Cell, 55 (1988) 1189-1193.
20. S. Fawell, J. Seery, Y. Daikh, C. Moore, L.L. Chen, B. Pepinsky, J. Barsoum, TAT-mediated delivery of heterologous proteins into cells, Proceedings of the National Academy of Sciences of the United STATes of America, 91 (1994) 664-668.
21. M. Popovic, M.G. Sarngadharan, E. Read, R.C. Gallo, Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS, Science, 224 (1984) 497-500.
22. S. Pantano, P. Carloni, Comparative analysis of HIV-1 TAT variants, Proteins: Structure, Function, and Bioinformatics, 58 (2005) 638-643.
23. E. Vives, P. Brodin, B. Lebleu, A Truncated HIV-1 TAT Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus, J. Biol. Chem., 272 (1997) 16010-16017.
24. B. Cornelissen, M. Hu, K. McLarty, D. Costantini, R.M. Reilly, Cellular penetration and nuclear imporTATion properties of 111In-labeled and 123I-labeled HIV-1 TAT peptide immunoconjugates in BT-474 human breast cancer cells, Nuclear Medicine and Biology, 37 (2007) 37-46.
25. S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, Y. Sugiura, Arginine-rich Peptides. AN ABUNDANT SOURCE OF MEMBRANE-PERMEABLE PEPTIDES HAVING POTENTIAL AS CARRIERS FOR INTRACELLULAR PROTEIN DELIVERY, J. Biol. Chem., 276 (2001) 5836-5840.
26. V. Polyakov, V. Sharma, J.L. Dahlheimer, C.M. Pica, G.D. Luker, D. Piwnica-Worms, Novel TAT-Peptide Chelates for Direct Transduction of Technetium-99m and Rhenium into Human Cells for Imaging and Radiotherapy, Bioconjugate Chem., 11 (2000) 762-771.
27. P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, J.B. Rothbard, The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proceedings of the National Academy of Sciences of the United STATes of America, 97 (2000) 13003-13008.
28. M. Kristensen, D. Birch, H. Mørck Nielsen, Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, International Journal of Molecular Sciences, 17 (2016) 185.
29. A. Ho, S.R. Schwarze, S.J. Mermelstein, G. Waksman, S.F. Dowdy, Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo, Cancer research, 61 (2001) 474-477.
30. A. Ziegler, Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans, Advanced Drug Delivery Reviews, 60 (2008) 580-597.
31. S. Futaki, Oligoarginine vectors for intracellular delivery: Design and cellular-uptake mechanisms, Peptide Science, 84 (2006) 241-249.
32. S. Lu, F. Zhao, Q. Zhang, P. Chen, Therapeutic peptide amphiphile as a drug carrier with ATP-triggered release for synergistic effect, improved therapeutic index, and penetration of 3D cancer cell spheroids, International journal of molecular sciences, 19 (2018) 2773.
33. V.-M. Le, M.-D. Lang, W.-B. Shi, J.-W. Liu, A collagen-based multicellular tumor spheroid model for evaluation of the efficiency of nanoparticle drug delivery, Artificial Cells, Nanomedicine, and Biotechnology, 44 (2016) 540-544.
34. A.M. Privalova, S.V. Uglanova, N.R. Kuznetsova, N.L. Klyachko, Y.I. Golovin, V.V. Korenkov, E.L. Vodovozova, E.A. Markvicheva, Microencapsulated multicellular tumor spheroids as a tool to test novel anticancer nanosized drug delivery systems in vitro, Journal of nanoscience and nanotechnology, 15 (2015) 4806-4814.
35. J. CARLSSON, K. NILSSON, B. WESTERMARK, J. PONTEN, C. SUNDSTROM, E. LARSSON, J. BERGH, S. PAHLMAN, C. BUSCH, V.P. COLLINS, FORMATION AND GROWTH OF MULTICELLULAR SPHEROIDS OF HUMAN ORIGIN, Int. J. Cancer 31 (1983) 523-533.
36. R.M. Sutherland, Cell and environment interactions in tumor microregions: the multicell spheroid model, Science, 240 (1988) 177-184.
37. J.P. Richard, K. Melikov, H. Brooks, P. Prevot, B. Lebleu, L.V. Chernomordik, Cellular Uptake of Unconjugated TAT Peptide Involves Clathrin-dependent Endocytosis and Heparan Sulfate Receptors, J. Biol. Chem., 280 (2005) 15300-15306.
38. M. Lindgren, M. Hällbrink, A. Prochiantz, Ü. Langel, Cell-penetrating peptides, Trends in Pharmacological Sciences, 21 (2000) 99-103.

Most read articles by the same author(s)

1 2 3 > >>